Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian A Gordon

Showing results (251-260 of 262) with videos related to

Pageof 27
Sort By:
Annals of Neurology|September 24, 2022
Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer DiseaseNelly Joseph-Mathurin, Jorge J Llibre-Guerra, Yan Li, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|October 28, 2017
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological PsychiatryPiotr Lewczuk, Peter Riederer, Sid E O'Bryant, et al.
Neurology|January 26, 2021
Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer DiseaseNelly Joseph-Mathurin, Guoqiao Wang, Kejal Kantarci, et al.
Nature Neuroscience|July 10, 2023
Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network (DIAN)Nicole S McKay, Brian A Gordon, Russ C Hornbeck, et al.
Molecular Psychiatry|March 23, 2019
The BDNF<sub>Val66Met</sub> SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's diseaseNicolai Franzmeier, Jinyi Ren, Alexander Damm, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 21, 2024
Presenilin-1 mutation position influences amyloidosis, small vessel disease, and dementia with disease stageNelly Joseph-Mathurin, Rebecca L Feldman, Ruijin Lu, et al.
The Lancet. Neurology|March 22, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J Bateman, Yan Li, Eric M McDade, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 23, 2025
Clinical use and reporting of neurofilament quantification in neurological disorders: A global overviewConstance Delaby, Aurélie Ladang, Jose Martinez-Yriarte, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
BiomarkersConstance Delaby, Aurélie Ladang, Jose Yriarte, et al.
Nature Medicine|June 22, 2021
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseStephen Salloway, Martin Farlow, Eric McDade, et al.
Pageof 27

Showing results (251-260 of 262) with videos related to

Sort By:
Pageof 27
Annals of Neurology|September 24, 2022
Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer DiseaseNelly Joseph-Mathurin, Jorge J Llibre-Guerra, Yan Li, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|October 28, 2017
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological PsychiatryPiotr Lewczuk, Peter Riederer, Sid E O'Bryant, et al.
Neurology|January 26, 2021
Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer DiseaseNelly Joseph-Mathurin, Guoqiao Wang, Kejal Kantarci, et al.
Nature Neuroscience|July 10, 2023
Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network (DIAN)Nicole S McKay, Brian A Gordon, Russ C Hornbeck, et al.
Molecular Psychiatry|March 23, 2019
The BDNF<sub>Val66Met</sub> SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's diseaseNicolai Franzmeier, Jinyi Ren, Alexander Damm, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 21, 2024
Presenilin-1 mutation position influences amyloidosis, small vessel disease, and dementia with disease stageNelly Joseph-Mathurin, Rebecca L Feldman, Ruijin Lu, et al.
The Lancet. Neurology|March 22, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J Bateman, Yan Li, Eric M McDade, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 23, 2025
Clinical use and reporting of neurofilament quantification in neurological disorders: A global overviewConstance Delaby, Aurélie Ladang, Jose Martinez-Yriarte, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
BiomarkersConstance Delaby, Aurélie Ladang, Jose Yriarte, et al.
Nature Medicine|June 22, 2021
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseStephen Salloway, Martin Farlow, Eric McDade, et al.
Pageof 27